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Centre, Manchester Academic Health Science Centre, University of
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Manchester, UK, 4Pharmacy Department, Royal Manchester Children's
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Introduction: Children admitted to paediatric and neonatal intensive
care units (P/NICUs) are at high risk from medication errors (MEs)
and preventable adverse drug events (pADEs).
Aim: To systematically review and critically appraise empirical studies
examining the prevalence and nature of MEs and pADEs in PICUs and
NICUs.
Method: Seven electronic databases were searched (January 2000 to
July 2017) as well as the grey literature. Quantitative observational
studies published in English reporting rates of MEs or pADEs in chil-
dren ≤18 years of age admitted to PICUs or NICUs were included.
Studies were heterogeneous in nature and were presented using
ranges or median with interquartile ranges (IQRs).
Results: Thirty‐six unique studies were eligible for inclusion, with the
majority originating from the United States of America (USA) (n = 10,
27.7%) and 21 (58.3%) being published from January 2010 onwards.
In PICUs, overall ME rates ranged from 5.7 to 48.8 per 100 medication
orders (n = 3) and 6.4 to 9.1 per 1000 patient days (n = 2). In NICUs,
MEs rates ranged from 5.5 to 77.9 per 100 medication orders (n = 2)
and from 4 to 35.1 per 1000 patient days (n = 2). Across both settings
prescribing and medication administration errors (P/MAEs) were
found to be most commonly associated with MEs and that dosing
errors were a common subtype of MEs. Most studies examined PEs
(n = 19, 52.8%) with a median prevalence of PEs per 100 orders of
13.3 (IQR 9.5‐29.55) in PICUs (n = 12) and 14.9 (IQR 4.25‐29.9) in
NICUs (n = 6). MAEs occurred in 28.9% of orders (n = 1) and 8.2%
of administrations (n = 1) in PICUs and ranged from 8.2% to 84.8%
of administrations in NICUs (n = 3). Rate of pADEs in NICUs ranged
from 0.47 to 14.38 per 1000 patient days (n = 2). A total of three stud-
ies in PICUs reported pADEs rates using different denominators.Pharmacoepidemiol Drug Saf. 2019;28(S1):3–16. wileyonlinelibraryCommonly involved drugs with MEs or pADEs were anti‐infectives,
analgesics, and sedatives in PICUs and anti‐infectives in NICUs.
Conclusion: MEs are a common problem in PICUs and NICUs. Our
review has identified important targets that could help set an
improvement agenda for both health care leaders and researchers.
There is also a need for research from countries outside of the
USA and for future work to explore in more detail outcomes such
as MAEs and pADEs that have received limited attention in the
current evidence base.Network meta‐analysis to estimate treatment
efficacy: The example of venous
thromboembolism prophylaxis strategies in
major orthopaedic surgeries
D.M. Dawoud1, S. Lewis2, J. Glen2, S. Dias3, C. Sharpin2
1University of Hertfordshire, Hatfield, UK, 2National Guideline Centre,
Royal College of Physicians, London, UK, 3University of York, York, UK
Aim: To review and synthesise the evidence from randomised con-
trolled trials (RCTs), which assessed the efficacy of venous thrombo-
embolism (VTE) prophylaxis strategies in people undergoing major
orthopaedic surgeries using network met‐analysis (NMA).
Methods: Systematic reviews of randomised controlled trials (RCTs)
assessing the efficacy of VTE prophylaxis in elective total hip
replacement (eTHR) and elective total knee replacement (eTKR)
were undertaken. The following databases were searched: The
Cochrane Library (CENTRAL), EMBASE, and Medline. Risk of bias
was assessed using The Cochrane risk‐of‐bias tool. Bayesian NMAs
of three outcomes (deep vein thrombosis (DVT), pulmonary embo-
lism (PE), and major bleeding [MB]), for each population, were
undertaken using the software WinBugs 1.4.3. The median (95%
credible intervals [CrIs]) relative risk (RR) and odds ratio (OR) com-
pared to no prophylaxis, ranks, and probability of being the best
were calculated.
Results: For eTKR, rivaroxaban for 14 days had the highest probability
of being the most effective in terms of DVT prevention (RR = 0.12,
95% CrI: 0.09‐0.56). Low‐molecular‐weight‐heparin (LMWH) at a
standard prophylactic dose (40 mg once daily) for 28‐35 days ranked
first in the pulmonary embolism (PE) network (RR = 0.02 [0.00‐
3.86]). LMWH at a low‐prophylactic dose for 14 days ranked first in
the MB network (OR = 0.08 [0.00 to 1.76]).© 2019 John Wiley & Sons, Ltd..com/journal/pds 3
4 SUPPLEMENT ARTICLESFor eTHR, rivaroxaban for 28‐35 days (RR = 0.06, 95% credible 0.29)
had the highest probability of being best in the DVT network. A strat-
egy of LMWH at a standard prophylactic dose for 10 days followed by
low‐dose aspirin for 28 days had the highest probability of being best
in the PE (RR = 0.0011 [0.00–0.096]) and MB (OR = 0.37 [0.00‐26.96])
networks, respectively.
The PE and MB networks' results were highly uncertain; with very
wide CrIs around the median estimates for both eTHR and eTKR.
Conclusion: Pharmacological prophylaxis strategies are more effective
compared to mechanical methods in the prevention of DVT, with
rivaroxaban ranked higher compared to other strategies. However,
this comes at the expense of a possible increase in major bleeding.
An outcome measure that reflects the impact of both VTE interval
(CrI): 0.01 and bleeding, for example quality of life, would be more
appropriate for guiding clinicians' decisions regarding the choice of
the optimal VTE prophylaxis strategy.
Disclaimer:
This work was undertaken by the National Guideline Centre (NGC),
Royal College of Physicians London, which received funding from
the National Institute for Health and Care Excellence (NICE). The
views expressed in this publication are those of the authors and not
necessarily those of the Institute.Design and initial testing of a virtual patient
as part of a workshop to improve
person‐centred care
S. Jacklin, N. Maskrey, S. Chapman
School of Pharmacy, Keele University, Keele, Staffordshire, UK
Aim: To develop and test a Virtual Patient (VP) for improving the abil-
ity of primary care professionals to consult in a person‐centred man-
ner and achieve shared decision‐making.
Methods: The VP was designed in a multi‐stage process; initial
scripting, patient involvement, and expert review. The initial script
was written by SJ, NM, and SC. SJ then met with three patients indi-
vidually to discuss the script and gather their suggestions for improve-
ment. These improvements were then implemented and a prototype
VP sent to the expert reviewers. Final changes were subsequently
made before the digital creation commenced.
Primary care pharmacists attended a good practice day in October
2017. The day featured a lecture, followed by group analysis of video
recorded consultations. After this, the attendees used the VP for
around 25 minutes before a whole group debrief. Four case studies
were completed by the participants, two at the start of the workshop,
two at end. The participants were asked to list three questions or
statements they would wish to ask/say to each case study patient.
These answers were rated by SJ as either technically‐centered, or
person‐centred; NM second rated them and any disagreement was
discussed. A paired t‐test in SPSS was used to determine whether
any change in the number of patient‐centred questions asked before
and after the day was significant.Results: A branched‐narrative VP was created that was accessible via
a website from a smartphone, tablet, or laptop. The entirety of the
consultation was simulated, from introductions and agenda setting
through to prescribing treatment, if the latter were required. The sce-
nario focused on whether or not to prescribe a statin for primary pre-
vention, and the patient was represented by autonomous, high‐quality
animation and voice over. The system provides feedback on the
learner's performance designed to encourage repetitive practice, in
line with Ericsson's theory of the acquisition of expertise (1993).
Thirty‐nine pharmacists completed the case study evaluation. 74% of
participants asked more person‐centred questions at the end of the
workshop compared to the start (n = 29); this change was statistically
significant (p < 0.0005).
Conclusion: VPs may facilitate the practice of person‐centred consul-
tation skills and shared decision‐making. It is unclear which compo-
nents of the workshop led to the change observed and whether or
not it led to a change in real world outcomes. Future research will
aim to explore this.
REFERENCES
Ericsson KA, Krampe RT, and Tesch‐Römer C. The role of deliberate prac-
tice in the acquisition of expert performance. Psychological review,
1993, 100(3), p.363
Note: Were this abstract to be presented orally, we would showcase
the VP live.
Prevalence and nature of medication errors
and medication related harm immediately
following hospital discharge from hospital to
community settings: A systematic review
*F.A. Alqenae1, D. Steinke1, R.N. Keers1,2
1Centre for Pharmacoepidemiology and Drug Safety, Division of
Pharmacy and Optometry, School of Health Sciences, University of
Manchester, Manchester, UK, 2Pharmacy Department, Greater
Manchester Mental Health NHS Foundation Trust, Manchester, UK
Background: The immediate time period post hospital discharge may
be associated with important risks to patient safety. Drug safety prob-
lems may occur at or following discharge such as communication
issues and medication changes which might manifest into safety risks
in the community such as medication errors (MEs) and related harm1,2.
Whilst some evidence exists relating to these safety risks at the point
of hospital discharge, there is comparatively little known about their
burden and nature in the immediate post‐discharge period in the
community.
Aim: Systematically identify and evaluate the available international
evidence on the prevalence and nature of medication errors and med-
ication related harm immediately following transition of care from hos-
pital to community settings.
Methods: The search was carried out between the dates January 1990
and September 2018, using the grey literature and 10 databases,
including; MEDLINE, EMBASE, CINAHL, PsycINFO, International
Pharmaceutical Abstracts, Health Management Information Consor-
tium, Cochrane Database of Systematic Reviews, Cochrane Central
SUPPLEMENT ARTICLES 5Register of Controlled Trials, Database of Abstracts of Reviews of
Effects, and Web of Science. No restrictions were applied on study
language, country, or population. Reference lists of included studies
and relevant review articles were also searched to identify relevant
citations. Studies were excluded if they focused on single drug, drug
class, or disease. Data from each study were extracted independently
by two reviewers. Quality assessment of the included studies was
completed using a validated framework3.
Results: Sixty‐nine studies met the inclusion criteria. Sixteen studies
(23%) reported MEs rates, nineteen studies (27.9%) reported rates
of unintentional medication discrepancies, twenty‐one studies
(30.4%) reported adverse drug reactions rates, and twenty‐four stud-
ies (34.7%) reported rates of adverse drug events (ADEs). A total of
30 (43.4%) studies originated from the in the United States, and 54
(78%); were published from the year 2010 onwards. Twenty‐two
(32%) studies data about severity of identified outcome measures.
The median rate of ADEs was found to be 18.8% (Inter Quartile
Range [IQR] 14‐29) (n = 23) and the median rate for MEs was found
to be 33% (IQR 19‐52) (n = 14) for adult and elderly patients. Het-
erogeneity was observed in the included studies in terms of outcome
definitions and data collection methods, which precluded meta‐
analysis. The most commonly reported medications associated with
post hospital discharge ADEs were antibiotics, antidiabetics, analgesic
medications, and cardiovascular drugs.
Conclusion: Medication errors and medication related harm are com-
mon immediately following transition of care from secondary to pri-
mary care. Standardisation of study design is an important target for
future research to reduce heterogeneity. Despite this, a number of
important targets were identified for future research that could guide
the development of successful remedial interventions.
REFERENCES
1. Forster A, Murff H, Peterson J, et al. “Adverse drug events occurring fol-
lowing hospital discharge”. J Gen Intern Med. 2005; 20(4): 317–323.
2. Mixon A, Myers A, Leak C, et al. “Characteristics associated with post
discharge medication errors”. Mayo Clin Proc 2014; 89(8): 1042–1051.
3. Allan E, and Barker K. “Fundamentals of medication error research”. Am
J Hosp Pharm. 1990; 47(3): 555–571.
Identifying indicators of potentially hazardous
prescribing related to mental health disorders
and medications: A systematic review
*W. Khawagi1,2, D. Steinke1, J. Nguyen1,3, R. Keers1,3
1Division of Pharmacy and Optometry, School of Health Sciences, Faculty
of Biology, Medicine and Health, University of Manchester, Manchester,
UK, 2Clinical Pharmacy Department, College of Pharmacy, Taif University,
Taif, Kingdom of Saudi Arabia, 3Pharmacy Department, Greater
Manchester Ment Health NHS Foundation Trust, Manchester, UK
Background: Measuring the safety of prescribing is vital to under-
standing and improving patient care. As a result, several sets of haz-
ardous prescribing indicators and criteria have been developed for
use across primary and secondary care settings. Despite the fact thatprescribing errors and medication‐related harm may be common in
patients with mental illness, there has been limited research focusing
on the development and application of potentially hazardous prescrib-
ing indicators, known as prescribing safety indicators (PSIs), specifi-
cally for this unique patient group.
Aim: Identify existing indicators of potentially hazardous prescribing
related to mental health (MH) medications and conditions from the
published literature.
Methods: A systematic search was conducted using seven electronic
databases: Embase, MEDLINE, PsycINFO, Web of Science, HMIC,
IPA, and CINAHL (from 1990 to November 2017). The bibliographies
of included studies and of relevant review articles were reviewed for
additional studies. Citation screening followed three phases; first,
studies which developed, validated or updated a set of explicit
medication‐specific indicators or criteria that measured prescribing in
terms of safety or quality were eligible for inclusion, irrespective of
whether they contained MH indicators or not. Second, relevant arti-
cles underwent further screening to extract any MH‐related indicators
(quality or safety), which was determined based on our operational
definition. Finally, two expert MH clinical pharmacists screened the
identified MH indicators and selected PSIs that described potentially
hazardous prescribing that could cause significant risk of harm. These
PSIs were categorised into seven prescribing problems and nine med-
ication categories.
Results: Seventy‐six unique studies were included, 67 of which
contained at least one MH‐related indicator along with five that spe-
cifically focused on indicators for populations with mental illness.
Among the 67 studies containing MH indicators, the elderly popula-
tion was the most commonly targeted (n = 36, 53.7%), and the most
common method for indicators validation was the Delphi method
(n = 32, 47.8%). A total of 1262 MH prescribing indicators were iden-
tified, with an average of 18 (SD = 24.7) per study (range 1–127); 245
of these were considered PSIs. Among the identified PSIs, the most
common type of prescribing problem was “Potentially inappropriate
prescribing considering diagnoses or conditions” (n = 106, 43.3%),
and the lowest was “omission” (n = 6, 2.4%). “Antidepressant” was
the most common medication category (n = 85, 34.7%) and “non‐
specific psychotropics” was the lowest (n = 1, 0.4%).
Conclusion: This is the first systematic review to identify a comprehen-
sive list of MH‐related indicators of potentially hazardous prescribing.
Examination of the types of indicators reported has revealed important
targets for new PSIs and will inform the development of a new
expanded suite of PSIs applicable to patients with mental illness.
Examining medication safety incidents in
in‐patient mental health settings: A 7‐year
analysis of incidents reported to the National
Reporting and Learning System
G.H. Alshehri1, R.N. Keers1,2, J. Nguyen2, A. Carson‐Stevens4,
D.M. Ashcroft1,3
1Centre for Pharmacoepidemiology and Drug Safety, Division of
Pharmacy and Optometry, School of Health Sciences, University of
Manchester, Manchester Academic Health Sciences Centre (MAHSC),
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Health NHS Foundation Trust, Manchester, UK, 3NIHR Greater
Manchester Patient Safety Translational Research Centre, Manchester
Academic Health Sciences Centre (MAHSC), University of Mancheste,
Manchester, UK, 4Division of Population Medicine, School of Medicine,
Cardiff University, Cardiff, United Kingdom
Background: Medication‐related problems are recognised as important
patient‐safety issue in mental health hospitals.(1) Based on our system-
atic reviewof 20 studies, the frequencyofmedication errors andadverse
drug events ranged from10.6 to 17.5 and 10.0 to 42.0 per 1000 patient‐
days, respectively.(2) In2006, theNationalPatientSafetyAgency (NPSA)
published a report examining medication safety incidents originating
mental health hospitals as reported to theNational Reporting and Learn-
ingSystem (NRLS) from2003until theendof September2005.(1)Whilst
informative, this report is now outdated and the medication incidents
reported were not analysed extensively in term of their nature, location
and severity. The present study, however, presents updated and more
extensive review of medication incidents over a 7‐year period.
Aim: To describe the nature and severity of medication safety inci-
dents reported within mental health hospitals across England and
Wales between 2010 and 2017.
Method: A retrospective reviewwas carried out of all medication safety
incidents submitted from in‐patient mental health units to the NRLS
between 2010 and 2017. A descriptive analysis was undertaken to
determine the number of medication incidents over time, and then to
characterise the incidents according to their nature, location, severity
and type of medication class involved. The University of Manchester's
Ethics Committee has exempted this study from formal ethical approval.
Result: A total of 94,159 medication incident reports were included,
the majority of which were due to medication errors (93,722;
99.5%). Ninety percent (85,099; 90.3%) originated from in‐patient
mental health services: mental health wards (71,993;76.5%), secure
units (11,149;11.8%), intensive care units (1,870;1.9%) and electro-
convulsive therapy unit (87;0.09%). Medication incidents from mental
health pharmacy services accounted for 6.4% (n=6,055) of the reports.
The type of inpatient mental health settings was not specified in
0.66% (n=623) of the reports or left blank by the reporter (2,382;
2.5%) Medication incidents occurred most frequently in the adminis-
tration stage (50,310; 53.4 %), followed by the prescribing
(15,549;16.5%) and dispensing (10,875; 11.5%) stages. Omitted med-
icine (17,210;18.2%), followed by wrong frequency (11,860;12.6%)
and wrong/unclear dose (10,251; 10.8%) were the types of medica-
tion errors most frequently reported. Medicines from central nervous
system were commonly reported (42,760; 44.3%) including antipsy-
chotics (15,053; 35.17%), followed by anxiolytics/hypnotics (8,141;
19.0%) and antidepressant (5,791; 13.53%). The clinical outcome anal-
ysis of the medication incidents demonstrated that 98.4% (n= 84,252)
of incidents resulted in no harm, whereas the remaining incidents
resulted in low harm (8,787;9.3%), moderate harm (1,076;1.1%),
severe harm (41; 0.04%), or death (4, 0.004%).
Conclusion: Our findings suggest that a tenth of medication incidents
reported in mental health hospitals resulted in harm to patients. Fifty
percent of incidents occurred in the medication administration stage,
with medication omission and antipsychotics being frequentlyimplicated. Further in‐depth analysis to understand the contributory
factors associated with these incidents is needed to improve medica-
tion safety in this setting.REFERENCES
1. National Patient Safety Agency. With safety in mind: mental health
services and patient safety.2006. http://www.nrls.npsa.nhs.uk/EasySite
Web/getresource.axd?AssetID=60040&.
2. Alshehri GH, Keers RN, Ashcroft DM. Frequency and Nature of Medica-
tion Errors and Adverse Drug Events in Mental Health Hospitals: a
Systematic Review. Drug Safety. 2017;40(10):871–86.Switching anticoagulation treatment during
inpatient stay—does it occur routinely?
M. Wilcock1, E. Dryden1, L. Kelly1, J.Y. Khoo2
1Pharmacy Department, Royal Cornwall Hospitals NHS Trust, Truro, UK,
23rd year pharmacy student, University of Nottingham, Nottingham, UK
Background: Anticoagulants (oral, injectable) are used for a variety of
indications with direct oral anticoagulants (DOACs) increasingly used
instead of warfarin in non‐valvular atrial fibrillation (NVAF) and venous
thromboembolism. Switching from warfarin to a DOAC in NVAF has
been described in a primary care setting.1 We wished to investigate
an observation from a GP that patients with NVAF admitted into hos-
pital on warfarin were being discharged home on a DOAC.
Aim: To utilise Hosp electronic prescribing system (EPS) to identify
patients admitted on warfarin and to ascertain which, if any anticoag-
ulant, they were discharged on, and to understand the rationale for
any patients with NVAF who had their anticoagulant switched.
Methods: Data on patients prescribed warfarin on day 1 or 2 of their
admission and who were discharged over 12 months to end of May
2018 were extracted from our EPS. This extract also identified the
anticoagulant prescribed on the discharge prescription. Discharge let-
ters and the medical notes for a subset of patients with NVAF were
examined. Data were analysed using Microsoft Excel. This study did
not require ethics approval.
Results: Therewere 1,105 episodes ofwarfarin prescribed at admission,
of which 261 (24%) were discharged on no anticoagulant, 691 (63%) on
warfarin alone, 92 (8%) on warfarin plus low molecular weight heparin,
and 61 (6%) discharged on an anticoagulant other than warfarin.
It is assumed that the majority of those without an anticoagulant on
their discharge prescription either had the drug temporarily withheld
whilst an inpatient or had a short hospital stay and so warfarin was
not recorded on their discharge prescription.
Of those discharged on a DOAC alone (38 episodes), a diagnosis of
NVAF at admission was clear in 17 cases (mean age 78 years, range
62 to 92).
Medical records were available for 12 of these patients. In 7/12
records, the switch from warfarin to a DOAC was deemed reasonable,
e.g. patient described as confused and unable to manage warfarin/INR
testing; patient also on dual antiplatelet therapy; and two instances of
a discussion with the patient about the switch to DOAC documented
SUPPLEMENT ARTICLES 7in the discharge letter. In 5/12 records, it was not obvious why the
switch had occurred.
In those five cases where medical records could not be scrutinised, it
was not clear in the e‐discharge letter why the switch had occurred.
Conclusion: Though we examined in detail those patients with NVAF
whose anticoagulant had been switched, in total, there were only 6%
(61/1105) patients admitted on warfarin for a variety of indications
discharged on a different anticoagulant. We conclude there was no
evidence of a routine policy to switch inpatients with NVAF on warfa-
rin to a DOAC. However, when patients are switched, documentation
in the e‐discharge letter as to the reason for the switch was not
explicit in 10/17 (59%) cases.
This study focused on a small subset of patients whose warfarin was
switched and results may not be generalizable.
REFERENCES
1. Fosbøl EL, Vinding NE, Lamberts M, Staerk L, et al., ‘Shifting to a non‐
vitamin K antagonist oral anticoagulation agent from vitamin K antago-
nist in atrial fibrillation’, Europace. 2018; 20(6):e78‐e86.
An audit of the use of direct oral
anticoagulants in the Mercy University
Hospital
A. Fleming1, C. Halleran2, E. Cagney2
1Pharmaceutical Care Research Group, School of Pharmacy, University
College Cork, Ireland, 2Department of Pharmacy, Mercy University
Hospital, Cork, Ireland
Introduction: The introduction of direct oral anticoagulants (DOACs)
has changed the landscape of anticoagulation with widespread clinical
use, replacing warfarin in many cases. However, they are not without
risk and inappropriate use (IU) with risk to patient safety has been
highlighted1.
Aim: To determine the appropriateness of DOAC usage, and the fac-
tors influencing prescribing, in the Mercy University Hospital (MUH)
Cork, Ireland.
Methods: A prospective, observational cohort study was conducted
from 1 December 2016 to 31 May 2017, on a sample of medical
and surgical wards in MUH. DOAC prescriptions for venous thrombo-
embolism (VTE) or atrial fibrillation (AF) were included. Patients post
hip or knee replacement were excluded. Prescriptions were reviewed
for appropriateness in accordance with prescribing criteria in the drug
summary of characteristics; indication, dose, frequency, duration, renal
function, drug interactions, and contraindications. Qualitative semi‐
structured, interviews were conducted with MUH doctors and phar-
macists in June 2017. Ethical approval was obtained and interview
participants provided written informed consent.
Results: A total of 159 DOAC prescriptions were reviewed (72.3%
male patient prescriptions). The median patient age was 76 years
(IQR 70–82 years). The most commonly prescribed DOAC was
apixaban (50%, n = 79), followed by rivaroxaban (41%, n = 66),
dabigatran (7%, n = 11), and edoxaban (2%, n = 3). The majority of pre-
scriptions were prescribed for AF (81%, n = 129), then VTE (17%,n = 27), with some cases of unlicensed use (2%, n = 7). In total, 72%
(n = 114) of all DOAC prescriptions were inappropriate. This inappro-
priate prescribing reached 57.9% (n = 92) of patients and were inter-
vened on by the ward pharmacist. The highest proportion of IU was
due to sub‐therapeutic dose (31.6%, n = 32) or supra‐therapeutic dose
(24.6%, n = 28). DOAC prescriptions where there had been transition
from another anticoagulant (eg, low molecular weight heparin) were
inappropriate in 19.3% of cases (n = 22). Drug interactions occurred
in 14% (n = 16) of prescriptions. There was a significant proportion
of apixaban deemed inappropriate (X2 = 5.48, p = 0.019).
Fourteen interviews were conducted (11 doctors, three pharmacists),
ranging in length from 4 to 21 minutes. Doctors reported their prefer-
ence for prescribing DOACs over warfarin due to reduced therapeutic
drug monitoring and the availability of an antidote for one DOAC. Par-
ticipants reported the transition between one type of anticoagulant to
a DOAC as a high‐risk period for under or over anticoagulation. Doc-
tors reported the need for prescribing workshops and clear guidelines,
especially for the peri‐operative period.
Conclusion: This study revealed a high level of inappropriate DOAC
use in our hospital and underlines the important of clinical pharmacist
prescription screening to prevent serious harm arising from inappro-
priate prescribing. Our findings highlight the need for clear and acces-
sible training opportunities and guidelines for prescribers, as well as
regular clinical audit and feedback to improve practice.
REFERENCES
1. Irish Medication Safety Network. Safety Alert Direct Oral Anticoagu-
lants http://www.imsn.ie/all‐news/20‐alerts/35‐doacs. (Accessed 5th
September 2018).
The contribution of digital technology in
supporting older people manage their
medicines
K. Warmoth, J. Frost, N. Britten
University of Exeter, Exeter, England
Background: With an ageing population, the concurrent use of multiple
medicines, or polypharmacy, is increasing. Multiple medicines and con-
ditions can have a considerable impact on an individual, and between
one‐half and one half of all medication prescribed for long‐term condi-
tions is not taken as recommended.1 Supporting community‐dwelling
older people tomanage their multiplemedicines is therefore imperative.
Aims: This review identifies and assesses which tools or resources are
available for older people to manage multiple medicines or complex
treatment regimens.
Methods: A scoping review2 was conducted. Electronic databases
(MEDLINE and CINAHL), grey literature, select paper citations, confer-
ence presentations, Cochrane Database of Systematic Reviews, and
key author publications were iteratively searched. English‐language
studies that included medicines self‐management tools were eligible.
Data extracted from included articles were categorised on the basis
of their utility, and the similarities and differences between tools were
mapped.
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are included in the review. Findings suggest that, firstly, most tools
are developed to ensure adherence—not medicine optimisation. Sec-
ondly, there has been a considerable growth in the development of
digital technology for medicines management in the last decade.
Lastly, it is unclear whether such tools are supporting medicines opti-
misation or mere adherence.
Conclusions: This review outlines the tools or resources, which may
be useful for older people to self‐manage multiple medicines, the evi-
dence for the use of different tools, and gaps in knowledge for further
research. It also questions the contribution of digital technology in
supporting older people to manage their medicines. Evidence about
such tools is warranted so that older people can maximise the use of
their medicines, and consequently reduce the societal costs of the
inappropriate use of medicines.
REFERENCES
1. National Collaborating Centre for Primary Care and Royal College of
General Practitioners Clinical Guidelines and Evidence Review for Med-
icines Adherence: Involving patients in decisions about prescribed
medicines and supporting adherence (2009). Nunes V, Neilson J,
O'Flynn N, et al.
2. Arksey, H., & O'Malley, L., “Scoping studies: towards a methodological
framework”, International Journal of Social Research Methodology,
2005; 8(1): 19–32.
Oral dosage form (ODF) modifications for
older adults: A direct observation of practice
in aged care facilities in Ireland
*L.J. Sahm, A.M. Crean, M. Kelly, A. Mc Gillicuddy
Background: ODF modifications (e.g. crushing or splitting tablets) can
potentially affect drug safety and efficacy; however, this is dependent
on factors including the medication, the dosage form, the method of
modification, and the subsequent method of administration. There
are a lack of data describing ODF modifications, particularly the
methods of modification and administration. In order to identify prior-
ity areas for intervention, there is a requirement for a thorough inves-
tigation of current ODF modification practices.
Aim: The aim of this study was to elucidate ODF modification and
administration practices in aged care facilities (ACFs) in Ireland using
undisguised, direct observation of drug rounds.
Methods: Undisguised, direct observations of medication administra-
tion to older patients on 13 wards in five ACFs in Ireland was under-
taken between May 2017 and July 2018. Patients who met the
following criteria were eligible to be included in the study: (1) resident
in the ACF; (2) aged ≥65 years; (3) received medication from nurses
during drug rounds; and (4) written, informed consent for inclusion
was provided (by the patient or their next‐of‐kin if the patient lacked
the capacity to consent). Demographic and medical details about
included patients were recorded from the patients' medical records.
The drug round observations were undertaken by one researcher
who recorded details including: the name, dose, dosage form, route,and method of administration of medication, as well as details of any
ODF modifications.
Results:Medicine administration to 141 patients (63.8% female, mean
age [SD] 83.96 years [7.26]) was observed. In total, 44.7% of patients
received at least one modified solid ODF during the observed drug
rounds. Amongst patients who received modified medicines, 46.0%
had medicines modified to overcome swallowing difficulties, 41.3%
to facilitate fractional dosing, and 12.7% required medicines to be
modified for both reasons. One hundred seventy‐eight instances of
modification were observed for 71 different medications, with drugs
acting on the Central Nervous System the most commonly modified.
Of these 178 modifications, 81.5% were unlicensed, and just under
half of these unlicensed modifications were authorised in the best
practice guidelines. Modified medicines were most frequently admin-
istered using food vehicles or thickened fluids, while almost one fifth
of non‐modified solid ODFs and liquid ODFs were administered with
thickened fluids or in food vehicles.
Conclusions: This study has provided important insights into ODF
modification and administration practices in ACFs in Ireland. ODF
modifications are commonly required to tailor oral medicines to meet
the swallowing capabilities and dosing requirements of older adults.
Whilst, many of the modifications were not authorised in either the
product licence or best practice guidelines, the majority of administra-
tion practices were optimised within the limitations of current
marketed formulations. Further research is needed to optimise medi-
cation formulation suitability for older adults and the findings of this
study, by describing the current reality of medication administration,
should inform the direction of this research.Improving pain management in patients with
a fractured neck of femur
M. Serag, E. Lim, L. Henderson
Northumbria Healthcare NHS Foundation trust, Cramlington, UK
Introduction: Patients with a fractured neck of femur (#NOF) are often
not prescribed rational or adequate analgesia post‐operatively. Patients
experiencing pain are slower tomobilise and have poorer health‐related
quality of life. This quality improvement initiative, as part of the HIPQIP
Scaling Up Improvement Programme, describes a multidisciplinary
approach to improving pain management in these patients with antici-
pated benefits on earlier mobilisation and length of stay.
Objective: To evaluate the progress and compliance of prescribers
with a standard analgesic prescribing regime as part of the fracture
neck of femur enhanced recovery pathway, and how this affects
mobilisation and length of stay.
Methods: In November 2016, a standardised, analgesia regime incorpo-
rating regular and when required oxycodone was agreed by the multi‐
disciplinary team. Analgesia prescribing and impact on mobilisation
pre‐ and post‐implementation was audited to assess effectiveness.
A 10‐patient re‐audit took place in December 2017 to evaluate com-
pliance with the prescribing protocol. A pre‐printed medication chart
was introduced in January 2018, to encourage further standardisation.
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quently commenced.
Time to mobilisation and its impact on length of stay pre and post‐
standardisation during these periods was also assessed as part of this
evaluation.
Results: Prior to establishment of an agreed protocol, there was a
wide variation in choice of analgesics and schedules prescribed. Varia-
tion reduced following agreement of a standardised regime, achieving
70% compliance Day 1 post‐op. Launch of a pre‐printed chart
improved standardisation with 100% compliance on Day 1 for 4 out
of the next 5 months. Introduction of electronic prescribing reduced
compliance initially to 50% due to unfamiliarity with the system, tran-
scribing errors from paper chart to electronic system, and the initiation
of newly qualified doctors in August 2018. In September 2018, com-
pliance had begun to return towards pre‐electronic prescribing rates
at 80% on Day 1 post‐op.
In addition, mobility was shown to improve with 100% patients being
able to mobilise Day 1 post‐op, an increase from 91%. The proportion
of patients mobilising with a zimmer frame increased from 43% to
71.5%, with the number mobilising with a zimmer frame either inde-
pendently or more than 5 metres with support, increasing from 13%
to 50.5%. This was accompanied by a reduction in length of stay from
22.5 days pre‐standardisation to 18.1 days post‐standardisation.
Conclusion: Introduction of a standardised pain protocol has been
achieved by working closely with all members of the multi‐disciplinary
team. Pre‐printing onto a medication chart ensured compliance across
all prescribers. Electronic prescribing has introduced challenges in
compliance with the protocol which should improve with familiarity
with the system. The revised protocol has led to improvements in
early mobilisation. Overall, the HIPQIP programme has demonstrated
a reduction in mortality from 8.1% to 4.9% and reduction in length
of stay to which this work may have contributed.Evaluation of polypharmacy reviews in
primary care
Introduction: Inappropriate polypharmacy, especially in older people,
imposes a substantial burden of adverse drug events, ill health, disabil-
ity, hospitalisation, and even death.1 To help address this, the local
CCG asked its general practices to conduct polypharmacy reviews
(PR) on 2% of their patient list, incentivised by a payment per patient.
Aim: The aim of this evaluation was to determine the number and
quality of PRs conducted by general practices and the resulting change
in repeat templates prescribed.
Method: Each general practice's SystemOne records were searched
for the period 1 April 2017 to 31 March 2018 to identify all patients
with a PR code. A detailed review of up to 10% of PRs for each gen-
eral practice was completed by an experienced pharmacist. Anony-
mous demographic and descriptive data were recorded for all
patients and summarised using summary statistics in Microsoft Excel
(2010). Sampled PRs were categorised according to review quality:
good (no additional actions identified), adequate (additional cost sav-
ing or minor clinical issues identified), inadequate (additional majorclinical issues identified), and not actioned (no recommended actions
taken) by the reviewing pharmacist.
Results: 5671 (198%) of a target of 2869 polypharmacy reviews were
conducted between 1 April 2017 and 31 March 2018. Table 1 shows
the mean age of patients reviewed and median number of repeat tem-
plates were similar across localities. The median change in number of
repeat templates and quality of PRs varied across localities, but would
equate to a 3752 reduction in repeat templates for all patients with a
PR.
Conclusion: Despite the ongoing workforce crisis, general practices
exceeded their PR targets with good and adequate reviews. These
reviews produced substantial reductions in repeat templates across
the area. Financial incentives for practices to conduct PRs can be suc-
cessful in tackling inappropriate polypharmacy.
REFERENCES
Scottish Government Polypharmacy Model of Care Group. Polypharmacy
Guidance, Realistic Prescribing 3rd Edition, 2018. Scottish GovernmentEvaluation of enhanced clinical pharmacy
service on older peoples wards
C. Barnes, T. Miller, C. Rezwana, A. McClean
Pharmacy Department, Northumberland, Tyne and Wear NHS
Foundation Trust, Newcastle Upon Tyne, UK
Aims/Objectives: Difficulties in recruiting medical staff led to skill mix
review and initial rollout of extended pharmacy service on older peo-
ple's wards in line with medicines optimisation agenda and CQC Key
lines of enquiry.
The aim of the service was:
1. To release medical staff time by providing an enhanced pharmacy
service.
2. To improve the quality of patient care by increased medicines
optimisation.
Methods: Two specialist clinical pharmacists were recruited to work
on two wards for 37.5 hours per week. In addition to NTW clinical
pharmacy service standards, the roles undertaken were:
• Transcribing all leave and discharge prescriptions.
• Transcribing all medication charts.
• Updating patient electronic medication records and related
assessments.
• Increased input at all stages of the patient journey.
• Increased contact with patients/carers for medication issues.
• Integrating with the MDT attending all meetings including the
72 hour and discharge meetings, improving quality and quantity
of clinical interventions.
• Medicine optimisation at the interface of care.
TABLE 1 Summary of patient and polypharmacy review (PR) characteristics for different localities
Locality
1
Locality
2
Locality
3
All
Localities
PR target 1164 863 843 2869
No. PRs conducted (% PR target) 2875 (247) 1582 (183) 1214 (144) 5671 (198)
Mean age patient with PR 76 71 74 74
Median (IQR) repeat templates at evaluation 8 (5, 11) 9 (5, 13) 9 (6, 12) 8 (5, 12)
No. (%) PR sampled 159 (6) 142 (9) 101 (8) 402 (7)
Change in no. repeat templates per
patient following PR
−0.3 −0.9 −0.9 −0.7
Number (% of reviewed PRs)
categorised as:
Good 44 (28) † 58 (41) † 15 (28)* † 117 (33) †
Adequate 89 (56) † 60 (43) † 30 (57)* † 179 (51) †
Inadequate 22 (14) † 8 (6) † 4 (8)* † 34 (10) †
Not actioned 4 (3) † 15 (11) † 4 (8)* † 23 (7) †
Estimated no. (% of target PR) or good/adequate quality for all patients 2405 (207) 1324 (153) 1031 (122) 4755 (166)
Abbreviations: PR, polypharmacy review; IQR, interquartile range. *Quality of PR was not evaluated for two practices due to a conflict of interest with the
reviewing pharmacist and to maintain anonymity of the practices; †Percentages total > 100% due to rounding.
10 SUPPLEMENT ARTICLESData was collected over a 3 and 6 month period to evaluate the
increased service.
Results
Approximately 8 hours doctors time was saved per week through writ-
ing of all leave and discharge prescriptions, rewriting charts, updates
to electronic medication records throughout the patient journey in
addition to other medicines optimisation tasks that would have previ-
ously been completed by a doctor.
1. Clinical interventions per patient (taken from entries on elec-
tronic care record in this time period) increased 5 fold on aver-
age per patient for both wards. This reflects the extra clinical
pharmacy input, contributions to patient care and patient
interactions.
2. Medicines reconciliation completed for 100% patients (average
trust‐wide is 87%).
Overwhelmingly positive feedback received from ward teams, includ-
ing medical staff
Conclusion: The success of the enhanced service has led to it being
rolled out to adult acute wards within the locality and potentially other
OPS wards Trust wide. Also, to review how skill mix can be further
embedded to utilise the skills of other pharmacy team members within
the service and pharmacist prescribing.
Assessment of the impact of a clinical
pharmacy service in the emergency
department of an acute teaching hospital in
Ireland
T.M. Barbosa1, E. Relihan3, G. Melanophy2, L. Keaveney1,2
1School of Pharmacy, University College Cork, Cork, Ireland, 2Pharmacy
Department, St. James's Hospital, Dublin, Ireland, 3Medication Safety St.
James's Hospital, Dublin, Ireland
Background: The Emergency department (ED) is recognised as a high‐
risk environment for patients1. Medication errors occurring in the EDhave the potential to impact patient's safety throughout their inpa-
tient stay2. Research is needed to determine the contribution of clini-
cal pharmacists in ED in Ireland.
Aim: To investigate the impact of introducing an ED clinical phar-
macy service by establishing the: (1) volume and type of clinical
pharmacist's activities in relation to medication reconciliation and
clinical review; (2) cost avoidance attributed to interventions; and
(3) timing of pharmacist encounter with patients in the ED in com-
parison to standard care.
Methods: Adult patients aged over 65 years, admitted via the ED,
were eligible for inclusion. Medication reconciliation was provided by
the clinical pharmacist, and a complete clinical review of the patient's
medication was undertaken. Medication discrepancies and additional
medication concerns were communicated to the relevant medical
teams. The clinical significance of these interventions was scored by
a peer review panel using a validated tool.
Results: Sixty patients were included in this study, of which 82%
required at least one clinical pharmacist intervention. One hundred
forty interventions were undertaken by the clinical pharmacist, i.e.
2.33 interventions per patient (range 0‐8). Themajority of interventions
(88%) were accepted by medical staff. Upon peer review analysis, 38%
of interventions were deemed to have the potential for “minor harm,”
59% of the interventions were deemed to have potential for “moderate
harm,” 1%were considered to have the potential for “severe harm,” and
the remaining 2% were considered to cause “no harm” to the patient.
Cost analysis demonstrated a cost avoidance of €10,131.71. The intro-
duction of an ED pharmacist resulted in patient reviews occurring, on
average, 27 hours earlier than standard care.
Conclusion: This analysis demonstrated the benefits, in relation to
both patient safety and cost savings, of an ED‐based clinical pharmacy
service.
REFERENCES
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SUPPLEMENT ARTICLES 11Venous thromboembolism prophylaxis
prescribing in renal impairment and extremes
of body weight
L.A. Ritchie, A.J. Basey, C. Lee
The Royal Liverpool and Broadgreen University Hospitals NHS Foundation
Trust, Liverpool, UK
Introduction: Hospital‐acquired venous thromboembolism (VTE)
accounts for 50%‐60% of all VTE and treatment is associated with a
considerable cost1. TheTrust policy recommends dalteparin 5000 units
subcutaneously (SC) daily for all eligible medical patients2. In those
with a creatinine clearance (CrCl) <30 ml/min, a dose of 2500 units
SC daily is recommended; in practice, estimated glomerular filtration
rate (eGFR) is used2. The Trust policy makes no recommendations
for weight‐based dosing and neither does NICE.1,2 Interestingly, the
Haemostasis Anticoagulation and Thrombosis (HAT) Committee rec-
ommends weight‐based dosing (Table 1)3.
Aim
1. To determine whether patients are prescribed prophylactic
dalteparin in line with Trust policy.
2. To identify any weight‐based prescribing of prophylactic
dalteparin, as per recommendations by the HAT Committee.
Methods: Raw data (including age, gender, hospital number, eGFR,
weight, and dalteparin dose or reason if not prescribed) were collected
retrospectively from 16 medical wards over five working days.
Results:
Renal function
There were 184 patients (92%) prescribed an appropriate dose of
dalteparin in line with Trust policy, 169 patients with an eGFR
>30 ml/min/1.73m2 were prescribed dalteparin 5000 units daily, and
15 patients with an eGFR <30 ml/min/1.73m2 were prescribed
dalteparin 2500 units daily.
Body weight
There were 5 patients (25%) weighing <50 kg with an eGFR
>30 ml/min/1.73m2 prescribed dalteparin 2500 units daily. There
were 12 patients weighing >100 kg with an eGFR >30 ml/min/
1.73m2, none were prescribed a weight‐based dose.
Conclusion: Most patients were prescribed a standard dose of prophy-
lactic dalteparin in line with Trust policy. There was some evidence of
weight‐based prescribing in patientsweighing <50 kg but not in patients
>100 kg, highlighting variability in prescribing practice. There is a risk of
underdosing (in overweight and obese patients) and overdosing (in
underweight patients) if standard doses of dalteparin are used as bodyTABLE 1 Weight‐based dosing recommendations for prophylactic
dalteparin
<50 kg 50‐100 kg 100‐150 kg >150 kg
Dalteparin 2500 units
daily
5000 units
daily
5000 units
twice daily
7500 units
twice dailyfat can affect the volume of distribution of dalteparin.4 Guidance on
when to useweight‐baseddosing is needed in order to standardise prac-
tice and optimise the efficacy and safety of VTE prophylaxis prescribing.
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thrombosis or pulmonary embolism. London. NG89. March 2018.
2. Prevention of thromboembolism (VTE) Policy [77]. The Royal Liverpool
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patients‐with‐high‐body‐weight/ (Accessed 9th October 2017).Use of CLOPIXOL ACUPHASE®
(ZUCLOPENTHIXOL acetate) on the inpatient
care wards within Northumberland Tyne and
Wear (NTW) NHS FOUNDATION trust
R. Ayre, C. Thomas, M. Morsy
Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle Upon
Tyne, UK
Aims/Objectives
The main objectives of the audit were to:
• Determine if the prescribing of Acuphase® was consistent with
its licenced indications.
• Determine if the rationale for prescribing Acuphase® was docu-
mented in the patient record (RiO) and if this was in line with
the NTW policy.
• Determine if monitoring was undertaken post Acuphase® admin-
istration in line with the NTW policy.
• Compare the use of Acuphase® across NTW, identifying any dif-
ferences in clinical practice needing further investigation.
There was limited assurance of compliance with the audit standards
for the use of Acuphase®:
• 97% of prescriptions were complaint with licenced indications for
the prescribing of Acuphase®, but two patients received greater
than the licencedmaximumdose over the 14‐day treatment period.
• 35% of patients did not have the rationale for use of Acuphase®
documented; 28% were in accordance with Trust policy.
• Only 10% received complete monitoring as required by the Trust
policy.
• One area of the trust accounted for 62% of the prescribing of
Acuphase®.
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the day of Acuphase® administration.
• Three patients received Acuphase® who were naive to antipsy-
chotic treatment.
A medical review of the patient before a dose was prescribed only
occurred in 50% of the administrations of Acuphase®.
Conclusions: Significant variations were found in the prescribing,
administration, and monitoring of Acuphase, and an improvement is
required. The audit results have been disseminated and discussed at
all levels of the trust. Awareness and training are occurring for all
members of the clinical team and specific clinical guidance on the
use of Acuphase to meet prescribing, and good clinical practice stan-
dards have been developed in collaboration with key prescribers iden-
tified by the audit. A re‐audit on the use of Acuphase will occur after
implementation of the clinical guidance.The impact of a ward‐based pharmacy
technician service in an IRISH hospital
E. Lynch1, J. O'Flynn1,2, C. O'Riordan2, C. Bogue2, D. Lynch2,
S. McCarthy1,2, K. Murphy1
1School of Pharmacy, University College Cork, Cork, Ireland, 2Pharmacy
Department, Cork University Hospital, Cork, Ireland
Introduction or Background (if relevant): Pharmacy technicians have
been employed in hospital settings for many years, but only recently
have their role been reviewed for potential expansion. Hospitals
across Australia, the United Kingdom, and many other countries have
implemented a ward‐based pharmacy technician service (1, 2), but this
is yet to become common practice in Ireland. At present, there is only
one published study on the development of the clinical role of phar-
macy technicians in Ireland (3).
Aim: The aim of this study was to determine if the expanded role of
the ward‐based pharmacy technician role could have a positive impact
on medicine management systems within a hospital ward.
Methods: This study was carried out over 8 weeks in an Irish hospital.
Sixteen wards were studied; four “intervention wards” which have the
ward‐based technician service in situ, and 12 “control ward” which
currently do not. Medicine management systems were assessed within
these wards with respect to (1) the presence of excess non‐ward stock
on drug trolleys, (2) the presence of expired medication on drug trol-
leys, and (3) the time taken by nurses to complete drug rounds.
Results: The total cost value of the excess non‐stock items found on
the intervention wards was €97.51 (the average cost per ward was
€24.38). The total cost value of the excess non‐stock items found on
the control wards was €13,767.76 (the average cost per ward was
€1,147.31). Eight expired medications were found on the control
wards; none were present on intervention wards. The ward‐based
technician service reduced the average nursing time to complete drug
rounds on a per‐patient basis by 28%.
Conclusion: This study has demonstrated that the expanded role of
the ward‐based pharmacy technician has had a positive impact inseveral ways; a reduction in the cost of non‐stock items present on
the ward along with a reduction in expired stock present. Time taken
to complete drug rounds was less on the intervention wards compared
to control wards, thus, freeing up time for nurses to engage in other
patient activities. Further studies should consider the full economic
costing of the ward‐based pharmacy technician service.
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eHealth Ireland: HSE; 2015Reducing the stigma in mental health through
shared learning—An evaluation of a joint
acute and mental health trust event
A. Young1, K. Smith2, C. Thomas1, R. Copeland2
1Pharmacy Department, Northumberland Tyne and Wear NHS
Foundation Trust, 2Pharmacy Department, Northumbria Healthcare NHS
Foundation Trust
Aims/Objective: To analyse the success and usefulness of the event
and whether it would change practice going forward to improve
patient care.
Method: An informal evening session was organised by respective
workforce leads within the two departments. It was decided to offer
refreshments and do the learning through facilitated case studies
whereby both patients' mental and physical health needs were
reviewed. For example, we looked at dementia and the use of antipsy-
chotics in delirium, lithium, and acute kidney injury, clozapine in some-
one with cardiovascular risks. A Survey Monkey was circulated after
each event to capture the views of participants and to ensure that it
was seen as a useful event.
Results: In total, around 60 members of the pharmacy team (pharma-
cists, technicians, and ATOs) attended the events, the majority being
pharmacists. In total, 28 responses were received.
• The event was rated as 4.3 out of 5 for usefulness to practice.
• 79% stating that the case studies were at the right level in terms
of balance between mental and physical health.
• 93% felt it raised their awareness of the interaction between
physical and mental health within their practice.
• 100% stated that they felt the event was a positive step towards
integration of services to improve patient care.
• Just under 60% had changed their practice as a result of the
knowledge gained.
Conclusions: Staff involved in the events found them extremely ben-
eficial and the positive outcome is that we believe patient care has
SUPPLEMENT ARTICLES 13improved as a result. Professional networks have increased and com-
munication between the acute and mental health trust, especially at
the interface is also improved.
Going forward acute trusts in our other geographical localities have
seen these events and are in the process of arranging similar ones.
Medicine information leaflets in Asia, Africa,
and the United Kingdom: A scoping review of
the literature
P. Nualdaisri1,2, S.A. Corlett2, J. Krska2
1Faculty of Pharmaceutical sciences, Prince of Songkla University,
Thailand, 2Medway School of Pharmacy, Universities of Kent and
Greenwich, UK
Background: Patient information leaflets (PILs) are a tool for enhanc-
ing patient safety of medicines. Providing patients with suitable infor-
mation is vital to encourage their appropriate use and understanding
of the likely benefits and risks of medicines.1 The provision of PILs
has been regulated in the United Kingdom since 1977,2 and much
research has been conducted in this area. A systematic review pub-
lished in 2007, which summarised research in written medicine infor-
mation, included no studies in either Asia or Africa.3
Aim: To review all studies on the provision of medicine information for
patients in Asia and Africa in comparison to studies in the United
Kingdom.
Methods: A literature review was carried out using Medline, CINAHL,
Web of Science, and Scopus to identify original articles focusing on
any aspect of medicine information from 2004 to 2017 in Asia, Africa,
and the United Kingdom. Empirical research and abstracts written in
English were included. Duplications were deleted. The articles were
sorted by country of origin and separated into three groups dependent
upon their main focus: (1) content and/or design, (2) patients' attitudes
towards PILs or the impact of PILs on knowledge or behaviour, and (3)
sources of medicine information used by patients.
Results: A total of 843 articles were identified. Six hundred ninet‐two
of these were excluded because they were either not conducted in the
target countries or not specific to medicine information. There were
23, 79, and 49 from Africa, Asia, and the United Kingdom, respec-
tively. In Africa, 11 studies focused on the impact of PILs on patients'
behaviour and six involved user testing. In contrast, a large proportion
of studies in Asia (40) assessed only the content of PILs, 19 were
patient surveys relating to sources of medicine information and rela-
tively few (9) assessed the impact of PILs. Almost all studies in the
United Kingdom either assessed impact of PILs on patients' under-
standing of information or involved user‐testing.
Group (1) studies on PILs mainly evaluated the content, by collecting a
wide variety of PILs and comparing them with either domestic or
international regulations, literature, or best evidence. Some studies
also evaluated readability utilising validated criteria, eg, Flesch‐Kincaid,
SMOG. In other studies, PILs were redesigned with new content such
as pictograms, headline sections or benefit information, often followed
by user testing.Group (2) studies involving patients were conducted to test the impact
of PILs in term of change in knowledge as well as assessing patients'
attitudes, acceptability, perceptions, and behaviour. These studies
used several methodologies including randomised controlled study,
before‐after method, and cross‐sectional surveys.
With regard to sources of medicine information, most group (3) stud-
ies used quantitative cross‐sectional surveys to identify different
sources used by patients to obtain medicine‐related information, with
PILs being one of these. A few articles were qualitative studies.
Conclusions: Studies on PILs undertaken in Africa and Asia are limited
in term of volume in comparison to research in the United Kingdom
and differ in their focus and methods used. The next stage is to assess
the quality of studies identified.REFERENCES
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Developing a novel information‐support app
for cancer clinical trials; findings from a
patient and public involvement and
engagement focus group
A.I. Chatzixenitidis1, A. Gifford1, B. Murray2, S.R. Chapman1
1School of Pharmacy, Keele University, Newcastle‐under‐Lyme, England,
2Royal Stoke University Hospital & Keele University Hospitals of North
Midlands NHS Trust, Stoke‐on‐Trent, England
Background: Mobile health (mHealth) can potentially provide patients
with readily available platforms to support their needs. As such plat-
forms are highly user‐orientated, developers need to consult with
potential users during the early development stage of these interven-
tions to ensure that they adequately reflect the needs of the end pop-
ulation (Darlow and Wen, 2016). This study presents the Patient and
Public Involvement and Engagement (PPIE) phase of the development
process of an app delivering information using avatars (virtual clini-
cians) for patients offered entry to a clinical trial for breast cancer.
Aims and objectives: To collect patients' perspectives in order to
establish the content and technical features of an app for consenting
to a breast cancer trial.
Methods: Four women with previous experience in clinical trials for
breast cancer were invited to attend a focus group. A semi‐structured
topic guide was used to facilitate the discussion, and framework anal-
ysis was deployed to analyse the findings.
14 SUPPLEMENT ARTICLESResults: Four main thematic categories were identified (experiences
from trials and perspectives on medical research; perceived informa-
tion needs; perspectives about using avatars and apps for information
and decision support; and recommendations about the app). Partici-
pants held favourable views about taking part in clinical research and
reflected positively upon their experiences with trials. The overall
feedback regarding the use of avatars was positive, and the prospect
of providing such an intervention to fellow patients was received well.
The perceived information needs were associated with general infor-
mation about trials and specific information about the trial they were
invited to, with particular emphasis upon safety and risk management.
Finally, the recommendations regarding the design of the app included
instructions about the avatars (customisation potential, professional
appearance, resembling characteristics of someone known to them),
ideas about the content (organisation of the content, framing of infor-
mation, and level of detail) and suggestions about the functions of the
app (glossary, section for explaining the trial to children, and timeline
of the trial).
Conclusions: The most significant findings were associated with the
content of the app and the appearance of the avatars. Participants
pointed out that the content should contain more than plain informa-
tion such as statistics or lists of side effects and be as explanatory as
possible in order to aid their understanding. With regards to the
appearance of the avatars, participants suggested that different ava-
tars should be used for delivering different types of information (e.g.
oncologists for the scientific information and nurses for emotional
support and sexual information) and that a separate avatar should be
formulated for explaining trials to their children, as another child or a
cartoon figure can potentially inspire more comfort than healthcare
professionals to them.
REFERENCES
1. Darlow S and Wen K, “Development testing of mobile health interven-
tions for cancer patient self‐management: A review”, Health
Informatics J, 2016; 22(3): 633–650.
Apixaban dosing for inpatients requires
pharmacist or specialist nurse input
M. Wilcock1, L. Kelly1, E. Dryden1, A. McSorley2
1Pharmacy Department, Royal Cornwall Hospitals NHS Trust, Truro,
2Lead Anticoagulant Nurse, Royal Cornwall Hospitals NHS Trust, Truro
Background: Apixaban requires complex dose adjustment for preven-
tion of thromboembolism in nonvalvular atrial fibrillation (NVAF). The
dose is 5mg twice daily, reduced to 2.5mg twice daily in patients with
severe renal impairment (creatinine clearance 15–29 mL/min), and
also in those with ≥2 of the following criteria: age ≥ 80 years, body
weight ≤ 60 kg, or serum creatinine (SCr) ≥ 133 micromole/L. The
rate of real world reduced dose prescribing is noted to be considerably
higher than the 4.7% seen in a pivotal trial1.
Aim: The aim was to measure compliance with apixaban dosing rec-
ommendations for NVAF in an inpatient setting in a 750 bedded
teaching district general hospital.Methods: Data were extracted from the hospital electronic prescribing
system for patients prescribed apixaban for any indication for
6 months to March 2018. Records for those with suspected inappro-
priate dosing due to age, weight, or SCr were viewed for clinical
details as necessary, including indication, e.g. for NVAF or other
thromboembolic disease. Data were analysed using Microsoft Excel.
This study did not require ethics approval.
Results: There were 447 patients prescribed apixaban—37.1% (166/
447) on 2.5mg dose and 62.9% (281/447) on 5mg dose, noting that
patients were treated for various indications, not exclusively NVAF.
Mean age of all patients was 77 years (84 years for those on 2.5mg
dose and 73 on 5mg dose). Only 96 patients had a weight documented
in the electronic prescribing system.
We identified 22 patients receiving 2.5mg dose for NVAF who did not
meet the criteria—Thirteen patients had none of the three criteria (age,
weight, SCr), and a further nine patients with a weight > 60 kg but
who had only one criterion (either age or SCr) for the low dose. This
is a minimum 13.3% of the total 166 low dose patients (some of whom
would have had this dose for indications other than NVAF).
There were also two patients on 5mg dose for NVAF who during their
admission had two of the three criteria (both aged over 80 years with
SCr ≥ 133 micromole/L) indicating they should be on 2.5mg.
Conclusion: There was apparent under dosing of apixaban in 22
patients with NVAF. This is a minimum of 13.3% (22/166) of our
patient cohort on low dose for any indication.
Limitations of our study include being located in just one hospital, no
knowledge of how many patients were actually treated for NVAF, a
documented weight was missing for many patients, and it was not
always clear if the hospital commenced treatment or the patient was
admitted on apixaban.
Others have reported on high proportion of patients in whom inappro-
priately low doses of apixaban are used2, generally because the clini-
cian perceives the patient to be at high bleeding risk.3
We intend to have education sessions to raise awareness of dosing
advice for clinical staff and encourage pharmacists to check more
closely apixaban dosing.
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teach counselling to clinical pharmacists—
development and proof of concept
C.L. Richardson, S. White, S. Chapman
School of Pharmacy, Keele University, Staffordshire, UK
SUPPLEMENT ARTICLES 15Background: Counselling can positively impact patient care, empower
patients to adopt self‐management of medicines and increase patient
satisfaction[1]. It is important that pharmacists providing drug‐specific
counselling are suitably trained with knowledge and skills. A virtual
patient (VP) tool on the topic of non‐vitamin K oral anticoagulants
(NOACs) to treat atrial fibrillation has been developed to teach phar-
macists NOAC counselling. The VP may be used for continuing profes-
sional development.
Aim: To develop and show proof of concept of the VP educational
tool.
Methods: A three‐way cyclic development approach was adopted
whereby the development team, a steering group, and Bayer AG as
the client informed VP design, content and aesthetic. The steering
group of pharmacists provided data for VP development, exploring
the VP concept. Their brief was to advise on the case to ensure it
was realistic, clinically accurate, and appropriate for use. This included
formal and informal evaluation; ethical approval was not required.
Feedback areas consisted of a number of VP elements: technological
feedback, text (clinical content and style), spoken text, pictures/visual
effects, and case feedback. During development, feedback was delib-
erated by the involved parties to inform design.
Results: Positive feedback on the VP concerned the technology and
the high‐standard of animations. Negative elements concerned inter-
national VP use and differences in practice. Feedback suggested that
the reviewers liked the VP concept but that delivery on different
devices could be improved. Some data supported that the smartphone
version was more usable than the computer version but one reviewer
was opposed to using a mobile phone for learning. The VP was
designed to be available on various devices, in keeping with the inten-
tion for the VP to be as accessible as possible.
The VP was reported to be “valuable” and realistic with high‐quality
animations. The VP's potential for training newly qualified pharma-
cists was highlighted. Suggested improvements included the option
to print or save a PDF of personalised feedback. This has now been
added to allow for written feedback to confirm learning. Written
feedback can also be used to document continuing professional
development.
Increased user feedback was suggested by the reviewers with pro-
posals of incorporating a pass/fail mark. The lack of a pass/fail mark
was an intentional design feature as there is not necessarily a “correct
answer” to the VP. It was hoped that this would empower participants
to reattempt the case and explore alternative pathways, as well as to
promote reflection, in keeping with pedagogy rationales of problem‐
based learning and theories of reflective learning through practice[2].
Conclusion: The VP met the needs of the client and their application.
Development was effective, in that a VP was created that is clinically
accurate, realistic, and useful, from the steering group's point of view,
demonstrating proof of the VP concept. This will inform future VP
development and encourage VP use in the pharmacy profession; a
large‐scale VP evaluation is underway.REFERENCES
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secondary care
S. Barrett, W. Baqir, D. Campbell, S. Ellis, N. Premchand
Background: Among all allergic reactions to antibiotics, penicillin is
one of the most commonly reported with 5%‐10% of patients having
a documented allergy to penicillin.[1] However, incidence of
penicillin‐related anaphylaxis has been reported to be in the region
of 0.01% to 0.04%.[2] A debate is growing on the nature of reported
allergy status, highlighting the association between reported allergy
status and a history of clinically significant IgE‐mediated reactions.[1]
Whilst work has demonstrated that clinicians considered history and
severity of allergy when selecting antibiotics in patients with an allergy
to penicillin recorded,[3] some authors suggest that half of allergies
reported by patients may not have an immunological origin.[4] This
raises concern in that patients with a documented penicillin allergy
may not receive first‐line penicillin‐containing treatments and instead
may be treated with second‐line agents. Second‐line agents may be
less cost‐effective, and the unnecessary overuse of these agents
may represent opportunities to improve patient treatment outcomes.
This study aimed to explore reported levels of penicillin allergy across
primary and secondary care.
Methods: Over a period of 1 week, all patients admitted to one hospi-
tal were audited for penicillin allergy status. A second study was car-
ried out to identify the number of patients with reported penicillin
allergy in electronic primary care records.
Results: An audit of hospital admissions (across Northumbria
Healthcare NHS Foundation Trust) over 4 weeks found 12%
(n = 326) of 2720 of patients had a documented penicillin allergy
whilst within primary care records, penicillin allergy status was
recorded in 6.2% (n = 77) of 1237 patients.
Conclusion: Across both settings, almost one in 10 patients are
recorded to be allergic to penicillin, thus being at risk of not receiving
optimal treatment if they needed it. Urgent work is needed to assess
these patients to identify those truly allergic. By doing so, we reduce
risk of harm, reduce healthcare costs, and protect limited antibiotic
agents against resistance.
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